Characteristics of studies of patients with BRCA1/2 mutated ovarian cancer.

<p><b>Histology</b>: pathological histology of ovarian cancer, se = serous ovarian cancer, CCC = clear cell cancer of, Mu = mucinous ovarian cancer. all = almost all of the epithelial ovarian cancer types, including serous, mucinous, clear cell cancer, etc.</p><p><b>Laboratory methods</b>: laboratory methods used to detect BRCA1/2 mutation, PTT = Protein truncation test, SSCP = Single-Strand Conformation Polymorphism, seq = sequencing, DGGE = fluorescent multiplex denaturing gradient gel electrophoresis, MLPA = multiplex ligation-dependent probe amplification, DHPLC = Denaturing high performance liquid chromatography, RFLP = Restriction fragment length polymorphisms, F-CSGE = Fluorescence-based Conformation Sensitive Gel Electrophoresis.</p><p><b>Germline/somatic</b>: Germ = germline mutation, Mixed = BRCA1 germline/somatic mutation or BRCA1 promoter methylation.</p><p><b>Mutation types:</b> VUS = variants of unknown significance.</p><p><b>Treatment</b>: chemotherapy used, 1 = only Platinum was used, 2 = Platinum-based chemotherapy, 3 = other agents without Platinum, like Paclitaxel, etc.